AIDSWEEKLY Plus; October 14, 2002
Michael Greer, Senior Medical Writer
"High levels of HIV-1 replication occur following perinatal infection and antiretroviral drugs may not fully suppress viral load during the early years of childhood," according to Jane Mullen and colleagues at King's College, Guy's and St. Thomas' Hospitals Trust, and St. George's Hospital in London. "Adherence to treatment may also be difficult among children."
These factors lead to a high rate of resistance mutations in children with HIV, especially among patients who do not respond to treatment, Mullen and coauthors said.
The researchers genotyped viral isolates from 26 children who failed to show virological suppression during antiretroviral therapy. All but two of these children were African, and 23 of the 24 African patients were infected with non-B HIV subtypes, they noted.
Roughly 90% of the children studied carried viral populations with resistance mutations in the reverse transcriptase gene, with protease resistance mutations seen in 33% of cases, according to the report. More than 90% of children carried viruses with resistant genotypes after unsuccessful lamivudine treatment, compared with 75% and 64% of those who failed to respond to nevirapine and zidovudine therapy respectively.
Adherence to treatment regimens fell below 90% in half of the study cohort (Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 2002 Nov;68(3):299-304).
"Antiretroviral drug resistance was common among this group of children failing therapy, the majority of whom were infected with non-B subtypes of HIV-1," Mullen and coauthors concluded. "As adherence to treatment was low in 50%, this was likely to be an important contributory factor."
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Mullen J, Leech S, O'Shea S, Chrystie IL, et al., "Antiretroviral drug resistance among HIV-1 infected children failing treatment", J Med Virol 2002 Nov;68(3):299-304
021014
AW021005
Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.